Morgan Stanley’s enGene Therapeutics ENGN Stock Holding History

Morgan Stanley’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$43.4K	Sell	21,685 -11,401	-34%	-$21.1K	﹤0.01%	6627
2026 Q2	$57.2K	Sell	33,086 -53,514	-62%	-$218K	﹤0.01%	6456
2026 Q1	$590K	Sell	86,600 -631,885	-88%	-$5.63M	﹤0.01%	5407
2025 Q4	$6.49M	Buy	718,485 +283,194	+65%	+$2.27M	﹤0.01%	3980
2025 Q3	$2.97M	Buy	435,291 +82,523	+23%	+$376K	﹤0.01%	4533
2025 Q2	$1.28M	Sell	352,768 -83,796	-19%	-$314K	﹤0.01%	4979
2025 Q1	$1.96M	Sell	436,564 -2,208	-0.5%	-$13.7K	﹤0.01%	4614
2024 Q4	$2.92M	Buy	438,772 +430,579	+5,255%	+$3.34M	﹤0.01%	4425
2024 Q3	$54.1K	Buy	8,193 +8,135	+14,026%	+$60.5K	﹤0.01%	6196
2024 Q2	$547	Buy	58 +50	+625%	+$641	﹤0.01%	7220
2024 Q1	$136	Hold	8	–	–	﹤0.01%	7345
2023 Q4	$74	Buy	+8	New	+$71	﹤0.01%	7388

Other funds holding ENGN

BCM

BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return

Aldebaran Capital Carmel, Indiana $139M AUM 35.88% 1-Year Est. Return

F.L. Putnam Investment Management Lynnfield, Massachusetts $9.33B AUM 30.52% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

Morgan Stanley's ENGN Position: Q3 2026 in Review

Morgan Stanley reduced its enGene Therapeutics (ENGN) stake by 34% in Q3 2026, selling an estimated $21.1K and leaving 21,685 shares worth $43.4K. The position accounts for ﹤0.01% of the portfolio, ranked #6627.

Morgan Stanley first reported a position in ENGN in Q4 2023 and has held it in 12 quarters since. The position peaked at $6.49M in Q4 2025. 33 funds tracked by Wall St. Rank hold ENGN as of Q3 2026.

Morgan Stanley held 21,685 shares of enGene Therapeutics worth $43.4K as of Q3 2026.
Morgan Stanley sold 11,401 enGene Therapeutics shares in Q3 2026, an estimated $21.1K.
enGene Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q3 2026, its #6627 holding.
Morgan Stanley first reported a position in enGene Therapeutics in Q4 2023 and has held it in 12 quarters since.
Morgan Stanley's enGene Therapeutics position peaked at $6.49M in Q4 2025.
33 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2026.

Based on Morgan Stanley's 13F filing for Q3 2026, filed 13 Nov 2026.